Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
OpenNational Institutes of Health · Opportunity number RFA-NS-28-012
Eligibility
Nonprofits are listed as eligible applicants.
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Independent school districts
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Special district governments
- State governments
- County governments
- City or township governments
- For profit organizations other than small businesses
- Public and state controlled institutions of higher education
- Private institutions of higher education
Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations. ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).
Funding
| Total program funding | $6,000,000 |
|---|---|
| Award floor | Not listed |
| Award ceiling | $2,500,000 |
| Category | Health |
| Assistance listing | 93.866, 93.NS1 |
Official sources
Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.